{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:26Z","timestamp":1792037366083,"version":"4.4.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Patients with locally advanced non\u2013human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti\u2013epidermal growth factor receptor (EGFR) antibody improves overall survival (OS) of patients with stage III to IV HNC, and preclinical data suggest that a small-molecule tyrosine kinase inhibitor dual EGFR and ERBB2 (formerly HER2 or HER2\/neu) inhibitor may be more effective than anti-EGFR antibody therapy in HNC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine whether adding lapatinib, a dual EGFR and HER2 inhibitor, to radiation plus cisplatin for frontline therapy of stage III to IV non-HPV HNC improves progression-free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter, phase 2, double-blind, placebo-controlled randomized clinical trial enrolled 142 patients with stage III to IV carcinoma of the oropharynx (p16 negative), larynx, and hypopharynx with a Zubrod performance status of 0 to 1 who met predefined blood chemistry criteria from October 18, 2012, to April 18, 2017 (median follow-up, 4.1 years). Data analysis was performed from December 1, 2020, to December 4, 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Patients were randomized (1:1) to 70 Gy (6 weeks) plus 2 cycles of cisplatin (every 3 weeks) plus either 1500 mg per day of lapatinib (CRT plus lapatinib) or placebo (CRT plus placebo).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was PFS, with 69 events required. Progression-free survival rates between arms for all randomized patients were compared by 1-sided log-rank test. Secondary end points included OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 142 patients enrolled, 127 (median [IQR] age, 58 [53-63] years; 98 [77.2%] male) were randomized; 63 to CRT plus lapatinib and 64 to CRT plus placebo. Final analysis did not suggest improvement in PFS (hazard ratio, 0.91; 95% CI, 0.56-1.46; <jats:italic>P<\/jats:italic>\u2009=\u2009.34) or OS (hazard ratio, 1.06; 95% CI, 0.61-1.86; <jats:italic>P<\/jats:italic>\u2009=\u2009.58) with the addition of lapatinib. There were no significant differences in grade 3 to 4 acute adverse event rates (83.3% [95% CI, 73.9%-92.8%] with CRT plus lapatinib vs 79.7% [95% CI, 69.4%-89.9%] with CRT plus placebo; <jats:italic>P<\/jats:italic>\u2009=\u2009.64) or late adverse event rates (44.4% [95% CI, 30.2%-57.8%] with CRT plus lapatinib vs 40.8% [95% CI, 27.1%-54.6%] with CRT plus placebo; <jats:italic>P<\/jats:italic>\u2009=\u2009.84).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and Relevance<\/jats:title><jats:p>In this randomized clinical trial, dual EGFR-ERBB2 inhibition with lapatinib did not appear to enhance the benefit of CRT. Although the results of this trial indicate that accrual to a non-HPV HNC-specific trial is feasible, new strategies must be investigated to improve the outcome for this population with a poor prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01711658\">NCT01711658<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3809","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:35:50Z","timestamp":1695915350000},"page":"1565","source":"Crossref","is-referenced-by-count":12,"title":["Radiotherapy Plus Cisplatin With or Without Lapatinib for Non\u2013Human Papillomavirus Head and Neck Carcinoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Stuart J.","family":"Wong","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Torres-Saavedra","sequence":"additional","affiliation":[{"name":"Department of Statistics, RTOG Foundation, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Shenouda","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Bumpous","sequence":"additional","affiliation":[{"name":"Brown Cancer Center, University of Louisville, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Chung","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel K.","family":"El-Naggar","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement K.","family":"Gwede","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burtness","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Tennant","sequence":"additional","affiliation":[{"name":"Brown Cancer Center, University of Louisville, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal E.","family":"Dunlap","sequence":"additional","affiliation":[{"name":"Brown Cancer Center, University of Louisville, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[{"name":"Brown Cancer Center, University of Louisville, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Stokes","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumon","family":"Rudra","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren K.","family":"Mell","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assuntina G.","family":"Sacco","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham Cancer Center, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Spencer","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham Cancer Center, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisle","family":"Nabell","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham Cancer Center, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yao","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio L.","family":"Cury","sequence":"additional","affiliation":[{"name":"Department of Oncology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrion L.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher U.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sutter Medical Center Sacramento, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Firat","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Contessa","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Galloway","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Currey","sequence":"additional","affiliation":[{"name":"Zablocki Veterans Affairs Medical Center, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Statistics, RTOG Foundation, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Walter J.","family":"Curran","sequence":"additional","affiliation":[{"name":"Genesis Care, Fort Myers, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi230049r1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CCO.0000000000000629","article-title":"Epidemiology of head and neck cancers: an update.","volume":"32","author":"Aup\u00e9rin","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"coi230049r2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi230049r3","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"coi230049r4","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10166","key":"coi230049r5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"coi230049r6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer.","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"coi230049r7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"coi230049r8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","article-title":"EGFR-targeted therapies in the post-genomic era.","volume":"36","author":"Xu","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"coi230049r9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network.","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"coi230049r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002881","article-title":"HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.","volume":"3","author":"Kong","year":"2008","journal-title":"PLoS One"},{"issue":"28","key":"coi230049r11","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"coi230049r12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.ejca.2012.11.023","article-title":"Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.","volume":"49","author":"Harrington","year":"2013","journal-title":"Eur J Cancer"},{"key":"coi230049r13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observation.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"coi230049r14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/rssb.1972.34.issue-2","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc A"},{"issue":"16","key":"coi230049r15","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi230049r16","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/annonc\/mdx344","article-title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and\/or metastatic head and neck cancer.","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann Oncol"},{"issue":"35","key":"coi230049r17","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","article-title":"Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study.","volume":"33","author":"Harrington","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2810008\/jamaoncology_wong_2023_oi_230049_1699901570.33505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:03:00Z","timestamp":1700150580000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2810008"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3809","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}